m+Medelevator.RU
← Поиск публикаций
Journal of hepato-biliary-pancreatic sciences · 2025

Natural History and Risk Factors of Splenic Infarction After Spleen-Preserving Distal Pancreatectomy Using the Warshaw Technique.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ebrahim Eyad, Chae Hochang, Kim Hyeong Seok, Yoon So Jeong, Shin Sang Hyun, Han In Woong, Heo Jin Seok, Kim Hongbeom

Аннотация

BACKGROUND: The Warshaw technique for spleen-preserving distal pancreatectomy (SPDP), which sacrifices splenic vessels, is widely used for benign and borderline malignant pancreatic diseases due to its technical simplicity. However, it carries the risk of splenic infarction. This study aimed to evaluate the incidence, risk factors, and clinical course of splenic infarction in patients who underwent SPDP using the Warshaw technique.

METHODS: Patients who underwent SPDP using the Warshaw technique at the Samsung Medical Center between 2007 and 2022 were retrospectively analyzed. Postoperative computed tomography scans were reviewed by a single researcher to classify splenic infarction severity based on the extent of infarction.

RESULTS: About 158 patients underwent the Warshaw technique. Splenic infarction was observed in 75 patients (47.5%). Among these, 34 cases (21.5%) were classified as severe (> 50%) infarction. Univariate and multivariate analysis identified previous abdominal surgery as the only statistically significant risk factor. Among the 75 patients with splenic infarction, two required antibiotic management, while none required radiological intervention.

CONCLUSION: Splenic infarction after SPDP using the Warshaw technique was clinically insignificant. These findings support the use of the Warshaw technique as a feasible and effective option for treating benign and borderline malignant pancreatic diseases.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты